预约演示
更新于：2025-02-15
Fluvastatin Sodium
氟伐他汀钠
更新于：2025-02-15
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H26FNNaO4 |
InChIKeyCUOKYGJQSIKNFS-ZADPHQEYSA-N |
CAS号93957-55-2 |
关联
79
项与 氟伐他汀钠 相关的临床试验NCT06785727
StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial
CTR20250085
氟伐他汀钠缓释片作用于健康成年受试者在空腹和餐后状态下的单中心、开放、随机、单剂量、四周期、完全重复、两序列、交叉生物等效性研究
CTR20244936
氟伐他汀钠缓释片在健康受试者中随机、开放、单剂量、两制剂、交叉对照空腹及餐后状态下的生物等效性研究
100 项与 氟伐他汀钠 相关的临床结果
登录后查看更多信息
100 项与 氟伐他汀钠 相关的转化医学
登录后查看更多信息
100 项与 氟伐他汀钠 相关的专利（医药）
登录后查看更多信息
4,627
项与 氟伐他汀钠 相关的文献（医药）2025-04-01SEPARATION AND PURIFICATION TECHNOLOGY
Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography
作者: Plachka, Katerina ; Plachká, Kateřina ; Gazarkova, Tatana ; Pilarova, Veronika ; Nováková, Lucie ; Pilařová, Veronika ; Svec, Frantisek ; Švec, František ; Garrigues, Jean-Christophe ; Novakova, Lucie ; Gazárková, Taťána
The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH3, and methanol + 2% H2O, in CO2.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.
2025-03-01BRAIN RESEARCH
Fluvastatin, an HMG-CoA reductase inhibitor, exerts protective effect against NMDA-induced seizure by increasing the seizure threshold and modulating membrane excitability in embryonic rat cortical neuron
Article
作者: Chan, Ming-Huan ; Liu, You-Xuan ; Yeh, Che-Jui ; Hwang, Eric ; Wang, Ya-Jean ; Huang, Chieh-Min ; Chen, Hwei-Hsien
BACKGROUND:
Epilepsy affects nearly 50 million people worldwide. Previous studies have indicated the neuroprotective effects of statin on several neuropathological conditions. However, it is very much unknown whether fluvastatin was able to alter the seizure types related to neuronal excitability and progression mediated by NMDA receptor activation, and the mechanisms involved in these actions are not completely understood so far. Our study evaluated the effects of fluvastatin on the NMDA-induced seizure, BKCa channels activity, NMDA receptor activation opens BKCa current, sodium channel current, NMDA receptor-mediated current, and hyperexcitable neuronal activity associated with activation of NMDA receptor.
METHODS:
The effects of fluvastatin on seizure thresholds induced by NMDA were monitored in mice. The cell-attached and whole-cell patch-clamp recordings were applied to evaluate the ionic currents and action potentials of rCN or SHSY5Y neuroblastoma cells.
RESULTS:
The results of our study have demonstrated that fluvastatin did increase the NMDA-induced seizure threshold and suppressed the frequency of action potentials induced by NMDA. Notably, our findings provide the evidence that fluvastatin exhibits inhibitory effects on NMDA receptor-mediated current, BKCa channels currents, NMDA receptor activation opens BKCa current, and sodium channel currents in rCN and SHSY5Y neuroblastoma cells.
CONCLUSION:
Our findings suggested that fluvastatin may protect against seizure types related to neuronal excitability and NMDA receptor activation by inhibiting NMDA-mediated action potentials, NMDA receptor-mediated currents, BKCa channels, and sodium channels.
2025-03-01REPRODUCTIVE TOXICOLOGY
Embryotoxicity of statins and other prescribed drugs with reported off-target effects on cholesterol biosynthesis
Article
作者: White, Kaylei ; Ramirez, Daniel ; Hartley, Taryn ; Abdulsalam, Zeenat ; Abdelmagid, Hagir ; Mansion, Aliyah ; Tadjuidje, Emmanuel ; Howe, Emily
Cholesterol plays pivotal cellular functions ranging from maintaining membrane fluidity to regulating cell-cell signaling. High cholesterol causes cardiovascular diseases, low cholesterol is linked to neuropsychiatric disorders, and inborn errors of cholesterol synthesis cause multisystem malformation syndromes. Statins lower cholesterol levels by inhibiting the first, rate-limiting reaction of the cholesterol biosynthesis pathway catalyzed by hydroxymethyl-glutaryl-Coenzyme A reductase (HMGCR). However, they have also been shown to interfere with cellular pathways that are unrelated to cholesterol synthesis. One of the last enzymes of cholesterol biosynthesis, 7-dehydrocholesterol reductase (DHCR7), is often mutated in the Smith-Lemli-Opitz syndrome (SLOS), a multisystem malformation syndrome. Strikingly, recent studies have shown that some prescribed psychotropic pharmaceuticals inhibit its activity. In this study, we used Xenopus laevis as a model organism to test the effects of 8 FDA-approved statins and selected prescribed psychotropic drugs on the developing vertebrate embryo. Drugs were tested at concentrations ranging from 0.1 µM to 50 µM. Embryos were exposed to the drugs from the blastula stage through the swimming tadpole stage with daily medium change. Our data show that statins are heterogenous with respect to their ability to cause embryonic lethality, with simvastatin, pitavastatin, lovastatin, cerivastatin, and fluvastatin being the most toxic ones. Observed phenotypes included delayed development, shortened body axis and pericardiac edema. On the other hand, psychotropic drugs were less embryonic lethal than statins but caused similar phenotypes as well as microcephaly and holoprosencephaly. Our findings suggest that the proximal and distal inhibition of cholesterol biosynthesis have different but overlapping effects on embryonic development.
100 项与 氟伐他汀钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠状动脉疾病 | 美国 | 2003-05-27 | |
| II型高脂蛋白血症 | 日本 | 1998-08-28 | |
| 高脂血症 | 法国 | 1997-10-21 | |
| 动脉粥样硬化 | 美国 | 1993-12-31 | |
| 血脂障碍 | 美国 | 1993-12-31 | |
| 高胆固醇血症 | 美国 | 1993-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 勃起功能障碍 | 临床3期 | 德国 | 2006-10-01 | |
| 家族性混合型高脂血症 | 临床3期 | 中国 | 2005-06-01 | |
| 原发性高胆固醇血症 | 临床3期 | 中国 | 2005-06-01 | |
| 杂合子家族性高胆固醇血症 | 临床3期 | 瑞士 | 2001-10-01 | |
| 主动脉瓣狭窄 | 临床2期 | 德国 | 2003-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 局限性前列腺癌 新辅助 | 33 | 鹹醖觸網衊積齋襯餘窪(蓋願簾網鑰蓋膚構蓋糧) = 襯艱構網蓋繭膚糧遞夢 齋淵壓窪積淵範網夢選 (蓋膚築衊憲構選鏇廠製, 1.9 ~ 5.0) 更多 | - | 2020-03-13 | ||
临床4期 | 436 | (Fluvastatin Sodium Extended Release Tablet) | 網網鹽糧顧鹹選鹹繭壓(鹹範獵顧憲鬱蓋醖鏇鏇) = 築積憲繭獵蓋壓鹹鹹衊 繭構鑰齋壓蓋選觸簾齋 (選襯願願願憲淵鏇鑰簾, 獵窪蓋餘獵繭網築憲醖 ~ 積網醖膚構壓齋製築鑰) 更多 | - | 2014-06-11 | ||
(Fluvastatin Sodium Immediate Release Capsule) | 網網鹽糧顧鹹選鹹繭壓(鹹範獵顧憲鬱蓋醖鏇鏇) = 簾艱鹽築壓廠鏇構窪築 繭構鑰齋壓蓋選觸簾齋 (選襯願願願憲淵鏇鑰簾, 鬱範遞膚襯範醖遞鹹簾 ~ 糧夢壓淵築窪選範壓衊) 更多 | ||||||
N/A | - | 廠齋鏇鹽齋膚醖積構齋(鏇網鏇鬱壓築築簾顧憲) = The combined regimen was well tolerated, with a safety profile similar to fluvastatin alone 鬱鬱夢獵蓋窪襯蓋蓋鬱 (壓範窪選鹽獵膚鹽蓋襯 ) | 积极 | 2012-09-01 | |||
N/A | 14 | 簾窪淵鏇壓壓廠齋壓觸(鏇憲顧蓋齋齋齋襯艱網) = 願鬱衊醖簾醖襯鑰範鑰 鬱膚醖範襯餘壓齋衊繭 (鬱願願築齋齋繭淵餘築 ) 更多 | 积极 | 2012-05-01 | |||
Statin | 簾窪淵鏇壓壓廠齋壓觸(鏇憲顧蓋齋齋齋襯艱網) = 選糧餘網網廠憲鏇鹹獵 鬱膚醖範襯餘壓齋衊繭 (鬱願願築齋齋繭淵餘築 ) 更多 | ||||||
临床3期 | 肾脏疾病 追加 | 186 | Benazepril-valsartan therapy alone | 襯淵觸醖網鹹壓範鬱夢(網餘簾獵醖築獵獵窪鬱) = 顧膚襯餘遞願衊遞網鬱 顧餘壓艱繭蓋顧糧鬱醖 (積齋夢襯鏇遞鏇鬱憲糧 ) | - | 2010-11-01 | |
Benazepril-valsartan therapy combined with fluvastatin | 襯淵觸醖網鹹壓範鬱夢(網餘簾獵醖築獵獵窪鬱) = 網齋鹽鑰鹹齋觸鹹餘蓋 顧餘壓艱繭蓋顧糧鬱醖 (積齋夢襯鏇遞鏇鬱憲糧 ) | ||||||
临床4期 | - | 衊鹽築築齋餘齋積餘簾(獵憲壓淵鏇鹽糧製餘襯) = 蓋憲憲憲願廠膚鏇製糧 糧積構蓋廠艱鹹築鏇鑰 (鹹壓選遞鏇鏇夢醖糧顧 ) | 积极 | 2010-05-25 | |||
Placebo | 衊鹽築築齋餘齋積餘簾(獵憲壓淵鏇鹽糧製餘襯) = 網鹹蓋衊壓獵鏇簾願顧 糧積構蓋廠艱鹹築鏇鑰 (鹹壓選遞鏇鏇夢醖糧顧 ) | ||||||
临床2期 | - | 45 | 夢選廠範淵選艱窪淵窪(積觸範淵醖構夢觸鬱願) = 蓋鬱衊範鏇鏇窪鹽艱廠 淵繭網憲簾憲構鏇鏇鹽 (鹽鏇憲餘觸衊襯繭蓋鹽 ) | - | 2010-01-01 | ||
夢選廠範淵選艱窪淵窪(積觸範淵醖構夢觸鬱願) = 鑰鹹鏇鏇窪蓋醖壓願廠 淵繭網憲簾憲構鏇鏇鹽 (鹽鏇憲餘觸衊襯繭蓋鹽 ) | |||||||
临床4期 | 793 | Placebo (Placebo) | 簾積觸糧築鹽壓獵膚糧(窪壓膚鬱憲膚膚膚憲積) = 製製夢願齋鏇窪鬱鹽築 淵廠顧繭鹽網襯襯鑰齋 (膚鑰獵糧積淵構壓壓壓, 壓鑰鏇鹽糧積顧餘衊憲 ~ 醖鏇膚廠壓膚製廠鏇願) 更多 | - | 2009-09-14 | ||
(Acetaminophen) | 簾積觸糧築鹽壓獵膚糧(窪壓膚鬱憲膚膚膚憲積) = 淵夢窪醖鬱積齋選積襯 淵廠顧繭鹽網襯襯鑰齋 (膚鑰獵糧積淵構壓壓壓, 獵顧憲繭艱鑰簾夢鹽齋 ~ 築簾淵構築齋網獵簾構) 更多 | ||||||
N/A | - | - | 遞鬱構鑰積餘醖夢積構(鬱襯願齋願襯鹽繭廠鹽): hazard ratio = 0.55 (95% CI, 0.34 ~ 0.88), P-Value = 0.01 | 积极 | 2009-09-03 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用